Whitelogolarge.jpg
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Looks into the Merger – RFP, SBTX, GBT, EVOP
September 26, 2022 09:52 ET | Monteverde & Associates PC
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Whitelogolarge.jpg
UPDATE – The M&A Class Action Firm Continues Investigating the Merger – RFP, SBTX, GBT, EVOP
September 22, 2022 17:26 ET | Monteverde & Associates PC
NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Whitelogolarge.jpg
The M&A Class Action Firm Continues Investigating the Merger – RFP, SBTX, GBT, EVOP
September 20, 2022 17:27 ET | Monteverde & Associates PC
NEW YORK, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
GBT new logo.png
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
September 15, 2022 18:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022,...
LOGO roboto color with gray.png
Folia Health Technology Platform Used in First-of-its-Kind Real World Evidence Study for Sickle Cell Disease
September 15, 2022 15:23 ET | Folia Health
BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Today, Folia Health announced the initiation of the ASCEND Study, a first-of-its-kind, at-home observational real-world evidence study in which people...
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
September 08, 2022 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA)...
Whitelogolarge.jpg
The M&A Class Action Firm Continues Investigating the Merger – BHVN, ONEM, GBT, CDEV
August 25, 2022 17:17 ET | Monteverde & Associates PC
NEW YORK, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
BES_Mark.jpg
GLOBAL BLOOD THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GBT and Encourages Investors to Contact the Firm
August 09, 2022 16:48 ET | Bragar Eagel & Squire
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
GBT new logo.png
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
August 08, 2022 06:45 ET | Global Blood Therapeutics, Inc.; Pfizer, Inc.
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential...
GBT new logo.png
GBT Announces New Employment Inducement Grants
August 04, 2022 16:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2022, the compensation committee of GBT’s board...